Comparison of efficacy and safety between standard-dose and modified-dose FOLFIRINOX as a first-line treatment of pancreatic cancer

Table 4 Adverse events (≥ Grade 3) n (%)

Event	sFOLFIRINOX	mFOLFIRINOX	P value
	(n = 88)	(n = 42)
Hematologic
Neutropenia	73 (83.0)	28 (66.7)	0.0441
Febrile neutropenia	24 (27.3)	9 (21.4)	0.474
Anemia	19 (21.6)	11 (26.2)	0.561
Thrombocytopenia	8 (9.1)	2 (4.8)	0.499
Non-hematologic
Fatigue	33 (37.5)	14 (33.3)	0.644
Anorexia	43 (48.9)	12 (28.6)	0.0291
Nausea/Vomiting	53 (60.2)	19 (45.2)	0.108
Diarrhea	12 (13.6)	0 (0.0)	0.0091
Peripheral sensory neuropathy	12 (13.6)	2 (4.8)	0.224
Sepsis	5 (5.7)	0 (0.0)	0.174
Lung infection	3 (3.4)	4 (9.5)	0.212
Biliary tract infection	6 (6.8)	0 (0.0)	0.176

¹Values indicate statistical significance. mFOLFIRINOX: Modified FOLFIRINOX; sFOLFIRINOX: Standard FOLFIRINOX.